FDA panel calls for clarity on duration of bone drug use, but sets no cutoff
This article was originally published in Scrip
Executive Summary
After a daylong discussion on the safety and effectiveness of use of bisphosphonates in preventing and treating osteoporosis, a US FDA advisory panel on 9 September in a 17-6 vote said the labelling of those drugs should clarify the duration of use, but that advice fell short of specifying a particular limit.